|
|
|
European Biopharmaceutical Review
|
|
Antibodies have been a major focus in biopharmaceutical research and development for the last two decades, ever since the first development of a process for the isolation of monoclonal antibodies (mAbs) in the 1970s. Following the FDA approval of the first therapeutic mAb in 1986 (1), and as a result of significant technological advances in the 1990s, mAbs and antibody fragments are now an increasingly important class of drugs. Reports from 2008 indicate that there are currently over 200 mAb candidates in clinical development (2), with 24 mAbs having been approved for therapeutic use (1).
Therapeutic antibodies in clinical use today cover a broad range of indications, including cancer, chronic inflammatory diseases, transplant rejection, infectious diseases and cardiovascular disease. The majority of antibody drugs are full-sized IgG forms, although there is increased interest in the use of antibody fragments, with three fragment-based drugs being approved for therapeutic use in the US.
ANTIBODY CLASSES, STRUCTURE AND FUNCTION
Human antibodies are grouped into five different isotypes (IgG, IgE, IgD, IgM and IgA) and then split further into sub-classes (IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) (see Figure 1). The different isotypes have distinct functions within the body.
Antibodies are relatively large globular proteins, consisting of two heavy chains (which define the isotype and subclass) and two light chains. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Dr Frank Detmers is Director of Ligand Application at BAC. In 2001, he received his PhD at the department of Molecular Microbiology at the University of Groningen (the Netherlands). He worked as a postdoctoral researcher at the Department of Cell Physiology at the Nijmegen Center of Molecular Life Sciences (NCMLS, Nijmegen, the Netherlands). He joined BAC in 2004 and the focus of his work is immobilisation of affinity ligands on solid supports and the development of applications of ligands in healthcare.
After receiving a Bachelors degree in Biochemistry, Pim Hermans joined the R&D department at Holland Biotechnology. In this group, he carried out research on the production and purification of recombinant cytokines and monoclonal antibodies for diagnostic and research purposes. In 1993, Pim joined the Bio-Immunochemistry group at Unilever-Bestfoods, where he was involved in the early development and exploration of camelid derived single domain antibodies (VHHs). Pim joined BAC in 2002. As Director of the Ligand Discovery Department, Pim is responsible for the development of VHH-based affinity ligands for applications in process, and analytical affinity chromatography. |
|
|
|
|
|
 |
News and Press Releases |
 |
Northway Biotechpharma Celebrates 15 Years of Growth and Success
Vilnius, Lithuania, July 16, 2019 ─ Northway Biotechpharma, a leading
biopharmaceutical contract development and manufacturing organization
(CDMO), celebrates its 15th anniversary today. As a midsized CDMO,
Northway Biotechpharma is able to provide flexibility and responsiveness
backed by a strong foundation in science and technology. The company
focuses on understanding its customers and meeting their specific needs
without binding them to one single approach. It is able to react rapidly
to unexpected project changes, adjusting timelines, capacities and
other activities to meet its customers’ evolving needs. On average,
Northway Biotechpharma has 25–30 development projects underway each
year, ranging from gene cloning to final drug product manufacturing.
More info >> |
|
 |
White Papers |
 |
|
Exploring Protein Stability by nanoDSF
NanoTemper Technologies GmbH
nanoDSF determines thermal and chemical protein stability with
ultra-high resolution and with unmatched reproducibility. The detection
of the intrinsic tryptophan and tyrosin fluorescence enables
measurements at close-to-native conditions in any buffer, even in the
presence of detergents. nanoDSF is applied in antibody engineering,
membrane protein research, formulation and quality control.
More info >> |
|
 |
Industry Events |
 |
World Vaccine Congress Europe
28-31 October 2019, Barcelona, Spain
The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona.
It’s the biggest and most established European vaccine event with over 250 speakers,
700+ senior vaccine attendees, hundreds of networking hours.
It cover key topics across the complete vaccine value chain bringing together:
• Government
• big pharma
• big biotech
• SME Biotech
• academia
and the wider service provider community and their partners to discuss scientific,
clinical and strategic advances and opportunities.
The event has already confirmed over 200 speakers from Human Vaccine Project, OECD,
CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more…
There is a Super Early Bird offer available – Find Out More
www.terrapinn.com/WVCEU/EBR
More info >> |
|
|
